Efgartigimod PH20 SC for Ocular Myasthenia Gravis

Market
100%75%50%25%0%Apr 20 • YES 70.0%Apr 20Apr 20 • YES 70.0%Apr 20Apr 20 • YES 70.1%Apr 20Apr 20 • YES 70.2%Apr 20
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
1/1/26
Study Completion
12/1/27
Sponsor
argenx
$ARGX
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
141
Volume
$22
NCT
NCT06558279
Trial Description
Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of efgartigimod PH20 SC by prefilled syringe in adults with ocular myasthenia gravis. Part A compares efgartigimod with placebo over about 7 weeks, followed by Part B in which all participants receive efgartigimod PH20 SC for up to about 2 years.